Showing 4071-4080 of 7172 results for "".
- CeraVe, Top Derms, and Skincare Enthusiasts Partner to Teach Consumers to #CleanseLikeaDermhttps://practicaldermatology.com/news/cerave-top-derms-and-skincare-enthusiasts-partner-to-teach-consumers-to-cleanselikeaderm/2461283/CeraVe is teaming up with board-certified dermatologists and two of the biggest dermatologist influencers on social media today – Dr. Dustin Portela (@208skindoc) and Dr. Michelle Henry (@drmichellehenry) – to host a global livestreamed event with skincare enthusiast and content creat
- The Foundation for Research and Education in Dermatology Welcomes Matt L. Leavitt, DO to Boardhttps://practicaldermatology.com/news/the-foundation-for-research-and-education-in-dermatology-welcomes-matt-l-leavitt-do-to-board/2461281/The Foundation for Research and Education in Dermatology (FRED), has named Matt L. Leavitt, DO as new member of its board. The Foundation says this decision marks the latest step in expanding its leadership at the executive and advisory levels. Dr. Leavitt is a board-certified derm
- CHMP Recommends European Approval of Nivolumab/Relatimab for Certain Melanomashttps://practicaldermatology.com/news/chmp-recommends-european-approval-of-nivolumabrelatimab-for-certain-melanomas/2461278/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of
- New from BTL: Meet The EMSCULPT NEO Edge Applicator for the Lateral Abdomenhttps://practicaldermatology.com/news/new-from-btl-meet-the-emsculpt-neo-edge-applicator-for-the-lateral-abdomen/2461265/BTL is launching the new Edge Applicators to treat the entire lateral abdomen. Shipping will begin in S
- Cynosure's New Tempsure eyeEnvi Handpiece Offers Improved Function and Greater Comforthttps://practicaldermatology.com/news/cynosures-new-tempsure-eyeenvi-handpiece-offers-improved-function-and-greater-comfort/2461258/Cynosure has added a new Tempsure eyeEnvi handpiece to its portfolio. Featuring innovative ergonomic pencil grip design and lighter piston tension required to activate the treatment, the company says the new handpiece is more comfortable for patients and providers, heating thinner tissue mor
- Vitamin D During Pregnancy May Cut Eczema Risk in Babieshttps://practicaldermatology.com/news/vitamin-d-during-pregnancy-may-cut-eczema-risk-in-babies/2461256/Taking Vitamin D supplements during pregnancy could substantially reduce the chances of babies developing atopic eczema, according to a new study by University of Southampton researchers. The research, published in the
- Phase 3 PSOARING 3 Long-Term Extension Study Data Positive for Tapinarof Creamhttps://practicaldermatology.com/news/phase-3-psoaring-3-long-term-extension-study-data-positive-for-tapinarof-cream/2461251/New data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3 long-term, open-label extension (“LTE”) study of Dermavant Sciences' VTAMA (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults was published in the
- FDA Approves Olumiant from Eli Lilly for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-olumiant-from-eli-lilly-for-alopecia-areata/2461231/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. FDA action marks the first approval of a systemic treatment for alopecia areata. Olumiant is
- Senté Launches Even Tone Mineral Sunscreenhttps://practicaldermatology.com/news/sente-launches-even-tone-mineral-sunscreen/2461230/Senté has launched Even Tone Mineral Sunscreen. The new tinted sunscreen formulas protect the skin from damage caused by visible light in addition to UV rays and are specifically designed to promote even skin tone in every complexion, the company says.
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a